• Twitter
  • LinkedIn
  • RSS
InterveXion Therapeutics
  • About Us
    • Overview
    • Management Team
    • Financial Conflict of Interest
  • Research & Development
    • Anti-Methamphetamine Products
    • Intellectual Property
    • Methamphetamine Use Disorder
  • Publications
    • Recent Publications
    • Anti-Methamphetamine Monoclonal Antibody
    • METH Vaccine
    • Anti-Phencyclidine Monoclonal Antibody
    • Review Articles
  • Contact Us
  • News
Select Page
Mailing Address:
4301 W. Markham #831
Little Rock, Arkansas 72205
Shipping Address:
401 S. Cedar St.
Little Rock, Arkansas 72205
Phone:
501.554.2377

7 + 9 =

Recent Posts

  • InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder
  • InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose
  • InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder
  • InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose
  • InterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder

Recent Comments

    Archives

    • October 2021
    • September 2021
    • April 2021
    • October 2020
    • May 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • May 2018
    • January 2018
    • October 2017
    • June 2017
    • January 2016
    • January 2015
    • November 2014
    • February 2014
    • August 2013
    • July 2013
    • December 2012
    • November 2012
    • May 2012
    • April 2012
    • July 2011
    • April 2011
    • October 2009
    • September 2009
    • March 2005
    • January 2005

    Categories

    • Anti-METH antibody, IXT-m200
    • Anti-METH Vaccine
    • Anti-PCP ch-mAb6B5
    • General News
    • Grants
    • METH in the news
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Twitter
    • LinkedIn
    • RSS
    © 2017 Intervexion